Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Andes

Showing results (1-10 of 207) with videos related to

Pageof 21
Sort By:
Bio-Protocol|May 1, 2015
Preparation of <i>Candida albicans</i> Biofilms for Transmission Electron MicroscopyHeather T Taff, David R Andes
Current Opinion in Infectious Diseases|May 19, 2021
Managing uncertainty in antifungal dosing: antibiograms, therapeutic drug monitoring and drug-drug interactionsRussell E Lewis, David R Andes
Seminars in Respiratory and Critical Care Medicine|December 15, 2011
Antifungal PK/PD considerations in fungal pulmonary infectionsAlexander J Lepak, David R Andes
Pharmacotherapy|May 19, 2005
Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safetySujata M Bhavnani, David R Andes
Antimicrobial Agents and Chemotherapy|July 22, 2024
Case Commentary: Extending our therapeutic range against multidrug-resistant <i>Candida</i>Max W Adelman, David R Andes
Current Opinion in Pharmacology|October 2, 2017
In vivo infection models in the pre-clinical pharmacokinetic/pharmacodynamic evaluation of antimicrobial agentsDavid R Andes, Alex J Lepak
Antimicrobial Agents and Chemotherapy|May 25, 2016
In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection ModelAlexander J Lepak, David R Andes
Microbiology Spectrum|September 24, 2015
Fungal Biofilms: In Vivo Models for Discovery of Anti-Biofilm DrugsJeniel E Nett, David R Andes
Cold Spring Harbor Perspectives in Medicine|November 12, 2014
Antifungal pharmacokinetics and pharmacodynamicsAlexander J Lepak, David R Andes
Infectious Disease Clinics of North America|April 22, 2019
Bacterial Infections in the Stem Cell Transplant Recipient and Hematologic Malignancy PatientElizabeth Ann Misch, David R Andes
Pageof 21

Showing results (1-10 of 207) with videos related to

Sort By:
Pageof 21
Bio-Protocol|May 1, 2015
Preparation of <i>Candida albicans</i> Biofilms for Transmission Electron MicroscopyHeather T Taff, David R Andes
Current Opinion in Infectious Diseases|May 19, 2021
Managing uncertainty in antifungal dosing: antibiograms, therapeutic drug monitoring and drug-drug interactionsRussell E Lewis, David R Andes
Seminars in Respiratory and Critical Care Medicine|December 15, 2011
Antifungal PK/PD considerations in fungal pulmonary infectionsAlexander J Lepak, David R Andes
Pharmacotherapy|May 19, 2005
Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safetySujata M Bhavnani, David R Andes
Antimicrobial Agents and Chemotherapy|July 22, 2024
Case Commentary: Extending our therapeutic range against multidrug-resistant <i>Candida</i>Max W Adelman, David R Andes
Current Opinion in Pharmacology|October 2, 2017
In vivo infection models in the pre-clinical pharmacokinetic/pharmacodynamic evaluation of antimicrobial agentsDavid R Andes, Alex J Lepak
Antimicrobial Agents and Chemotherapy|May 25, 2016
In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection ModelAlexander J Lepak, David R Andes
Microbiology Spectrum|September 24, 2015
Fungal Biofilms: In Vivo Models for Discovery of Anti-Biofilm DrugsJeniel E Nett, David R Andes
Cold Spring Harbor Perspectives in Medicine|November 12, 2014
Antifungal pharmacokinetics and pharmacodynamicsAlexander J Lepak, David R Andes
Infectious Disease Clinics of North America|April 22, 2019
Bacterial Infections in the Stem Cell Transplant Recipient and Hematologic Malignancy PatientElizabeth Ann Misch, David R Andes
Pageof 21